Veru’s Enobosarm Shows Promise in Preserving Muscle During Weight Loss

A groundbreaking Phase 2b study by Veru Inc. has revealed promising results for enobosarm, a muscle-preserving agent, in older adults experiencing significant weight loss. Conducted with 168 participants aged over 60 receiving the GLP-1 receptor agonist WEGOVY®, the trial demonstrated enobosarm’s ability to protect lean body mass, enhance fat reduction, and maintain physical function. Patients on enobosarm experienced a statistically significant decrease in fat mass and retained more muscle compared to those on WEGOVY® alone, a vital outcome for addressing age-related frailty and improving quality of life.

“These findings are exciting and address an unmet medical need,” said Dr. Louis Aronne, a leading obesity expert. With plans to advance to Phase 3 trials, Veru aims to further evaluate enobosarm’s long-term impact, including its potential to support sustainable weight management after GLP-1 therapy. The company is also preparing to meet with the FDA to align on the next regulatory steps, reinforcing enobosarm’s role as a novel approach to improving body composition in an aging population.